Published in Obesity and Diabetes Week, January 16th, 2006
The main objective of these studies is to identify well-tolerated and safe doses of E1-I.N.T. in diabetes patients, and signs of efficacy by measuring parameters including insulin usage and HbA1c levels. Preliminary data from the first four type 1 diabetes patients completing the 4 week treatment period (E1-I.N.T. or placebo) showed a reduction in daytime insulin usage and a favorable safety profile when the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week